Brief: Equillium Announces Interim Results From EQUALISE Study

Equillium

27/09/2022 12:25

Sept 27 (Reuters) - Equillium Inc  EQ.O :
    * EQUILLIUM ANNOUNCES POSITIVE INTERIM RESULTS FROM EQUALISE
STUDY
IN SUBJECTS WITH LUPUS NEPHRITIS
    * EQUILLIUM INC - ITOLIZUMAB CONTINUES TO DEMONSTRATE
FAVORABLE
SAFETY AND TOLERABILITY THROUGH SIX MONTHS OF TREATMENT
    * EQUILLIUM INC - LOOK FORWARD TO CONTINUING TO ENROLL
PATIENTS IN
TYPE B PORTION OF EQUALISE STUDY AND ANTICIPATE SHARING TOPLINE
DATA IN MID-2023
    * EQUILLIUM - 83% SUBJECTS ACHIEVED COMPLETE OR PARTIAL
RESPONSE
AND 67%SUBJECTS ACHIEVED > 80% REDUCTION IN UPCR BY WEEK 28
    * EQUILLIUM INC - 67% SUBJECTS ACHIEVED >50% REDUCTION IN
UPCR
    * EQUILLIUM INC - ITOLIZUMAB WAS GENERALLY SAFE AND WELL
TOLERATED
WITH NO DRUG RELATED SERIOUS ADVERSE EVENTS OR TREATMENT
DISCONTINUATIONS
    * EQUILLIUM INC - TOP-LINE DATA FROM TYPE B PORTION OF
EQUALISE
STUDY IN PATIENTS WITH LUPUS NEPHRITIS IS EXPECTED TO BE
ANNOUNCED MID-2023

Source text for Eikon:  ID:nBwbJ1s08a 
Further company coverage:  EQ.O 
 ((Reuters.Briefs@thomsonreuters.com;))